Genentech files license application to use Avastin in breast cancer

By Elaine Rigoli

Tampa, Fla., May 25 - Genentech, Inc. has submitted a supplemental Biologics License Application with the Food and Drug Administration for Avastin in combination with taxane chemotherapy for patients who have not previously received chemotherapy for their locally recurrent or metastatic breast cancer.

Genentech said it has requested priority review of the application, which means that if accepted, the FDA would make its decision on the application within six months of the agency's receipt of the submission, or in November 2006.

Avastin is approved as a first-line treatment for metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy.

Genentech is a biopharmaceutical company located in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.